Open AccessCorrelation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer
Author(s) -
MeeSook Roh,
Neul-Bom Yoon,
Seul Lee,
Bohyoung Kang,
Soo-Jung Um,
Dong-Hyun Lee,
Choonhee Son
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_515_18
Subject(s) - digital polymerase chain reaction , epidermal growth factor receptor , liquid biopsy , t790m , cold pcr , lung cancer , mutation , concordance , cancer research , pathology , mutation rate , biopsy , somatic cell , melting curve analysis , biology , cancer , polymerase chain reaction , point mutation , medicine , gene , gefitinib , biochemistry
Somatic mutations of the gene encoding epidermal growth factor receptor (EGFR) are detected in approximately 30%-50% of patients with non-small cell lung cancers (NSCLC), so detection of EGFR mutation is the pivotal step of treatment in patients with advanced NSCLC. However, difficulty in obtaining sufficient tissue and bias from the heterogeneity of the tumor samples are the major obstacles. Although analyzing EGFR with circulating tumor DNA (ctDNA) in plasma is a breakthrough, accuracy is the problem in variable methods. Peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis (PANAMutyper ® ) is a novel and highly sensitive method of detecting EGFR mutation in tumor tissues.